Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.25 USD | -3.68% | -3.35% | -34.43% |
May. 31 | Piper Sandler Starts Apellis Pharmaceuticals With Neutral Rating, $46 Price Target | MT |
May. 24 | Apellis Pharmaceuticals, Sobi Say Pegcetacoplan Reduces Post-Transplant Kidney Diseases | MT |
Business Summary
Number of employees: 704
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Therapeutic Compounds
100.0
%
| 75 | 100.0 % | 397 | 100.0 % | +425.83% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 75 | 100.0 % | 397 | 100.0 % | +425.83% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Founder | 54 | 09-09-24 | |
Cedric Francois
FOU | Founder | 51 | 09-09-24 |
Timothy Sullivan
DFI | Director of Finance/CFO | 53 | 17-09-30 |
Caroline Baumal
CTO | Chief Tech/Sci/R&D Officer | 57 | 23-01-02 |
Nur Nicholson
CTO | Chief Tech/Sci/R&D Officer | 55 | 20-07-31 |
Adam Townsend
COO | Chief Operating Officer | 47 | 18-11-19 |
Lukas Scheibler
CTO | Chief Tech/Sci/R&D Officer | 53 | 19-03-31 |
Meredith Kaya
IRC | Investor Relations Contact | - | - |
Jeffrey Eisele
PRN | Corporate Officer/Principal | 62 | 20-08-31 |
Vahe Ghahraman
LAW | General Counsel | - | 19-03-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Alec Machiels
FOU | Founder | 51 | 09-09-24 |
Director/Board Member | 65 | 13-06-30 | |
Paul R. Fonteyne
BRD | Director/Board Member | 62 | 20-04-05 |
Andrew Dunlop
BRD | Director/Board Member | 52 | 10-02-28 |
Cedric Francois
FOU | Founder | 51 | 09-09-24 |
Founder | 54 | 09-09-24 | |
Lok Chung Chan
CHM | Chairman | 73 | 13-06-30 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 121,365,555 | 103,981,403 ( 85.68 %) | 0 | 85.68 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.43% | 4.76B | |
-2.29% | 89.87B | |
-3.95% | 37.57B | |
-13.07% | 32.75B | |
+63.05% | 26.47B | |
-22.14% | 14.25B | |
-7.96% | 12.99B | |
-9.33% | 11.93B | |
-46.33% | 10.84B | |
+5.77% | 9.11B |
- Stock Market
- Equities
- APLS Stock
- Company Apellis Pharmaceuticals, Inc.